MA49749A - Anticorps anti-cd137 - Google Patents

Anticorps anti-cd137

Info

Publication number: MA49749A
Authority: MA; Morocco
Prior art keywords: antibody
Prior art date: 2017-08-01

Application number

MA049749A

Other languages

English (en)

Inventor

Christopher Carl Frye

Michael Dewain Kalos

Helen Kotanides

Stephanie Lynn Sandefur

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-08-01

Filing date

2018-07-25

Publication date

2021-03-24

2018-07-25 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2021-03-24 Publication of MA49749A publication Critical patent/MA49749A/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

MA049749A 2017-08-01 2018-07-25 Anticorps anti-cd137 MA49749A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201762539687P	2017-08-01	2017-08-01

Publications (1)

Publication Number	Publication Date
MA49749A true MA49749A (fr)	2021-03-24

Family

ID=63165504

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA049749A MA49749A (fr)	2017-08-01	2018-07-25	Anticorps anti-cd137

Country Status (23)

Country	Link
US (1)	US10906983B2 (fr)
EP (2)	EP4070811A1 (fr)
JP (2)	JP6743320B1 (fr)
KR (2)	KR102344620B1 (fr)
CN (1)	CN111182919B (fr)
AU (2)	AU2018311804B2 (fr)
BR (1)	BR112020001441A2 (fr)
CA (2)	CA3146758A1 (fr)
CL (1)	CL2020000233A1 (fr)
CO (1)	CO2020001050A2 (fr)
CR (1)	CR20200042A (fr)
DO (1)	DOP2020000020A (fr)
EA (1)	EA202090204A1 (fr)
EC (1)	ECSP20007663A (fr)
ES (1)	ES2912651T3 (fr)
IL (1)	IL272349B2 (fr)
JO (1)	JOP20200016B1 (fr)
MA (1)	MA49749A (fr)
MX (1)	MX2020001351A (fr)
PH (1)	PH12020500225A1 (fr)
SG (1)	SG11202000747VA (fr)
UA (1)	UA128388C2 (fr)
WO (1)	WO2019027754A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11512134B2 (en)	2017-08-01	2022-11-29	Eli Lilly And Company	Anti-CD137 antibodies
CA3069438A1 (fr)	2017-07-11	2019-01-17	Compass Therapeutics Llc	Anticorps agonistes qui lient cd137 humain et leurs utilisations
CN111182919B (zh) *	2017-08-01	2023-07-07	伊莱利利公司	抗cd137抗体
WO2019089753A2 (fr)	2017-10-31	2019-05-09	Compass Therapeutics Llc	Anticorps cd137 et antagonistes pd-1 et leurs utilisations
US11851497B2 (en)	2017-11-20	2023-12-26	Compass Therapeutics Llc	CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
US20210054089A1 (en) *	2018-03-23	2021-02-25	Eli Lilly And Company	Anti-cd137 antibodies for combination with anti-pd-1 antibodies
US12037406B2 (en) *	2018-03-23	2024-07-16	Eli Lilly And Company	Anti-CD137 antibodies for combination with anti-PD-L1 antibodies
CN112334488B (zh) *	2018-07-19	2023-12-08	伊莱利利公司	靶向免疫检查点的双特异性抗体
US20200407440A1 (en)	2019-04-24	2020-12-31	Magenta Therapeutics, Inc.	Amatoxin antibody-drug conjugates and uses thereof
AU2020308463A1 (en)	2019-06-26	2022-02-17	Ap Biosciences, Inc.	Antibodies for T-cell activation
TW202144395A (zh) *	2020-02-12	2021-12-01	日商中外製藥股份有限公司	用於癌症之治療的抗cd137抗原結合分子
KR20230135571A (ko)	2020-11-25	2023-09-25	상하이 준셀 테라퓨틱스 컴퍼니 리미티드	종양 침윤 림프구 배지 및 이의 응용

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003049755A1 (fr) *	2001-10-09	2003-06-19	Mayo Foundation For Medical Education And Research	Amelioration des reponses immunitaires par des agents liant 4-1bb
US7288638B2 (en) *	2003-10-10	2007-10-30	Bristol-Myers Squibb Company	Fully human antibodies against human 4-1BB
KR101527300B1 (ko) *	2010-09-09	2015-06-09	화이자 인코포레이티드	4-1ｂｂ 결합 분자
JP2018508509A (ja) *	2015-02-22	2018-03-29	ソレント・セラピューティクス・インコーポレイテッド	Ｃｄ１３７に結合する抗体医薬
GB201619648D0 (en) *	2016-11-21	2017-01-04	Alligator Bioscience Ab	Novel antibodies and uses thereof
CN111182919B (zh) *	2017-08-01	2023-07-07	伊莱利利公司	抗cd137抗体

2018
- 2018-07-25 CN CN201880064332.2A patent/CN111182919B/zh active Active
- 2018-07-25 EP EP22159268.6A patent/EP4070811A1/fr not_active Withdrawn
- 2018-07-25 CR CR20200042A patent/CR20200042A/es unknown
- 2018-07-25 WO PCT/US2018/043632 patent/WO2019027754A1/fr active Application Filing
- 2018-07-25 CA CA3146758A patent/CA3146758A1/fr active Pending
- 2018-07-25 MX MX2020001351A patent/MX2020001351A/es unknown
- 2018-07-25 EP EP18752950.8A patent/EP3661544B1/fr active Active
- 2018-07-25 BR BR112020001441-9A patent/BR112020001441A2/pt unknown
- 2018-07-25 MA MA049749A patent/MA49749A/fr unknown
- 2018-07-25 ES ES18752950T patent/ES2912651T3/es active Active
- 2018-07-25 JO JOP/2020/0016A patent/JOP20200016B1/ar active
- 2018-07-25 AU AU2018311804A patent/AU2018311804B2/en active Active
- 2018-07-25 UA UAA202000367A patent/UA128388C2/uk unknown
- 2018-07-25 KR KR1020207002814A patent/KR102344620B1/ko active IP Right Grant
- 2018-07-25 SG SG11202000747VA patent/SG11202000747VA/en unknown
- 2018-07-25 IL IL272349A patent/IL272349B2/en unknown
- 2018-07-25 US US16/497,493 patent/US10906983B2/en active Active
- 2018-07-25 EA EA202090204A patent/EA202090204A1/ru unknown
- 2018-07-25 KR KR1020217041897A patent/KR20210158420A/ko not_active Application Discontinuation
- 2018-07-25 CA CA3071383A patent/CA3071383C/fr active Active
- 2018-07-25 JP JP2020505392A patent/JP6743320B1/ja active Active
2020
- 2020-01-29 CL CL2020000233A patent/CL2020000233A1/es unknown
- 2020-01-29 CO CONC2020/0001050A patent/CO2020001050A2/es unknown
- 2020-01-30 PH PH12020500225A patent/PH12020500225A1/en unknown
- 2020-01-31 EC ECSENADI20207663A patent/ECSP20007663A/es unknown
- 2020-01-31 DO DO2020000020A patent/DOP2020000020A/es unknown
- 2020-07-29 JP JP2020128427A patent/JP7257364B2/ja active Active
2021
- 2021-12-02 AU AU2021277707A patent/AU2021277707A1/en active Pending

Also Published As

Publication number	Publication date
EP3661544A1 (fr)	2020-06-10
EP3661544B1 (fr)	2022-04-13
JP2020527356A (ja)	2020-09-10
CA3071383C (fr)	2022-04-12
IL272349B2 (en)	2024-09-01
KR20210158420A (ko)	2021-12-30
NZ761548A (en)	2024-07-05
CO2020001050A2 (es)	2020-02-18
CN111182919B (zh)	2023-07-07
AU2021277707A1 (en)	2021-12-23
PH12020500225A1 (en)	2020-11-09
CL2020000233A1 (es)	2020-07-31
JP2020182492A (ja)	2020-11-12
CA3071383A1 (fr)	2019-02-07
DOP2020000020A (es)	2020-02-28
AU2018311804B2 (en)	2021-09-02
ECSP20007663A (es)	2020-06-30
WO2019027754A1 (fr)	2019-02-07
IL272349B1 (en)	2024-05-01
EP4070811A1 (fr)	2022-10-12
US20200377607A1 (en)	2020-12-03
CR20200042A (es)	2020-03-03
CN111182919A (zh)	2020-05-19
EA202090204A1 (ru)	2020-05-22
SG11202000747VA (en)	2020-02-27
KR102344620B1 (ko)	2022-01-03
IL272349A (en)	2020-03-31
JP7257364B2 (ja)	2023-04-13
JOP20200016B1 (ar)	2022-10-30
MX2020001351A (es)	2020-03-09
KR20200023439A (ko)	2020-03-04
JP6743320B1 (ja)	2020-08-19
CA3146758A1 (fr)	2019-02-07
JOP20200016A1 (ar)	2020-01-28
UA128388C2 (uk)	2024-07-03
ES2912651T3 (es)	2022-05-26
BR112020001441A2 (pt)	2020-08-04
US10906983B2 (en)	2021-02-02
AU2018311804A1 (en)	2020-02-13

Publication	Publication Date	Title
FR21C1030I2 (fr)	2022-04-08	Conjugué anticorps anti-her2-médicament
MA47694A (fr)	2021-05-19	Anticorps anti-tigit
MA49034A (fr)	2020-02-12	Anticorps anti-lag3
EP3903817A4 (fr)	2022-08-17	Nouvel anticorps anti-ccr8
MA47268A (fr)	2019-11-20	Anticorps anti-gpc3
MA52884A (fr)	2021-04-21	Anticorps anti-il-11
MA53434A (fr)	2021-12-01	Anticorps anti-tigit
EP3423089A4 (fr)	2019-10-23	Anticorps anti-tigit
MA49749A (fr)	2021-03-24	Anticorps anti-cd137
DK3625259T3 (da)	2024-07-08	Anti-sirpalpha-antistoffer
EP3503920A4 (fr)	2020-05-06	Anticorps anti-ctla4
EP3334757A4 (fr)	2019-04-03	Anticorps anti-tigit
MA45004A (fr)	2019-03-27	Anticorps spécifiques anti-wt1-hla
MA46272A (fr)	2019-07-31	Anticorps anti-cd27
MA50352A (fr)	2020-08-19	Anticorps multispécifiques
EP3359573A4 (fr)	2019-05-29	Marquage d'anticorps
MA47472A (fr)	2019-12-18	Anticorps
DK3504241T3 (da)	2024-08-19	Anti-cd3-antistofformuleringer
EP3383915A4 (fr)	2019-07-24	Anticorps anti-pd-1
MA44236A (fr)	2018-12-26	Anticorps anti-tgfbêta 2
MA52366A (fr)	2021-03-03	Anticorps anti-tl1a optimisés
DK3606961T3 (da)	2022-07-04	Garp-tgf-beta-antistoffer
MA52152A (fr)	2021-01-20	Anticorps
MA51134A (fr)	2021-03-24	Anticorps anti-alpha-synucléine
MA42843A (fr)	2018-07-25	Anticorps anti-cd115